BriaCell Therapeutics Corp - Ordinary Shares - New
XNAS:BCTX 4:00:00 PM EDT
| Market Cap (Intraday) | 16.75M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $9.58 |
| 50-Day MA | $10.73 |
| 200-Day MA | $21.25 |
BriaCell Therapeutics Corp - Ordinary Shares - New Stock, XNAS:BCTX
Bellevue Centre, 235 -15th Street, West Vancouver, British Columbia V7T 2X1
Canada
Phone: +1.604.921.1810
Number of Employees: 18
Description
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMTâ„¢ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.